LeonaBio, Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand LeonaBio’s performance over the past year. My goal is to turn complex filing data into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

LeonaBio is a clinical-stage biotech company. This means they aren't selling medicine yet; they are still in the lab and testing phase. They focus on two main areas: cancer treatments (specifically metastatic breast cancer using a drug called lasofoxifene) and nervous system diseases (using a drug called ATH-1105 for ALS).

2. Financial performance: Still in the "spending" phase

Because they have no product on the market, they aren't making a profit. For the year ending December 31, 2024, the company lost $42.5 million. Most of this—$35 million—went toward research and development. They spend about $3.2 million every month on clinical trials, labs, and staff. With a public market value of only $9.9 million, they are a "micro-cap" company, meaning their stock can be difficult to buy or sell in large amounts.

3. Major wins and hurdles

• The Sermonix Deal: LeonaBio signed a deal with Sermonix Pharmaceuticals to develop and sell lasofoxifene in specific regions. They received $2 million upfront and could earn up to $45 million more if their clinical trials succeed and regulators approve the drug.
• Funding: They raised $15 million through a private investment. However, they missed a deadline to file a required report (Form 8-K). Because of this, they cannot use a "shelf registration" to raise money easily for the next year. They must now use a more expensive and slower process to raise cash.

4. Financial health and "Runway"

The company has $18 million in cash. They have no long-term bank debt, but they owe $12 million to former partners if they hit certain research goals. At their current spending rate, they have about 5 to 6 months of cash left. Without more funding or a major partnership, they will run out of money by late 2025.

5. Key risks

• The "All-or-Nothing" Nature: The company’s value depends entirely on their two drugs. If a trial fails to show that a drug works, the stock price could drop 70-90% overnight.
• Dilution: Because they lose money and have little cash, they will need to sell more shares to stay afloat. This will likely reduce your ownership percentage by 30-50% over the next 18 months.
• Competition: They are fighting against giants like Pfizer and Eli Lilly. These companies have much bigger budgets and established networks, which could make LeonaBio’s drugs obsolete even if they are approved.

6. Future outlook

The path ahead is steep. Success depends on two things: raising more money before their cash runs out and getting positive test results for lasofoxifene. These results are the main factor that could attract a buyer or a new partner.

Final Thought for Investors: LeonaBio is a high-risk, speculative investment. Because they are burning through cash quickly and face significant regulatory and competitive hurdles, this company is best suited for those who are comfortable with the possibility of losing their entire investment in exchange for the potential of a breakthrough in their clinical trials. Before buying, consider whether you are prepared for the high likelihood of share dilution and the company's tight 2025 funding deadline.